Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
02 03 2021
Historique:
received: 21 04 2020
revised: 02 01 2021
accepted: 05 02 2021
entrez: 3 3 2021
pubmed: 4 3 2021
medline: 27 1 2022
Statut: ppublish

Résumé

Cancer cells use actin-based membrane protrusions, invadopodia, to degrade stroma and invade. In serous ovarian cancer (SOC), the endothelin A receptor (ET

Identifiants

pubmed: 33657382
pii: S2211-1247(21)00114-5
doi: 10.1016/j.celrep.2021.108800
pii:
doi:

Substances chimiques

ARHGEF7 protein, human 0
ARRB1 protein, human 0
Actin Depolymerizing Factors 0
Antineoplastic Agents 0
EDNRA protein, human 0
Endothelin A Receptor Antagonists 0
Endothelin-1 0
Phenylpropionates 0
Pyridazines 0
RAC3 protein, human 0
Receptor, Endothelin A 0
Rho Guanine Nucleotide Exchange Factors 0
beta-Arrestin 1 0
integrin-linked kinase EC 2.7.1.-
PAK1 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
p21-Activated Kinases EC 2.7.11.1
rac GTP-Binding Proteins EC 3.6.5.2
ambrisentan HW6NV07QEC

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108800

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Ilenia Masi (I)

Unit of Preclinical Models and New Therapeutic Agents, IRCCS - Regina Elena National Cancer Institute, Rome 00128, Italy.

Valentina Caprara (V)

Unit of Preclinical Models and New Therapeutic Agents, IRCCS - Regina Elena National Cancer Institute, Rome 00128, Italy.

Francesca Spadaro (F)

Confocal Microscopy Unit, Core Facilities, Istituto Superiore di Sanità, Rome 00161, Italy.

Lidia Chellini (L)

Unit of Preclinical Models and New Therapeutic Agents, IRCCS - Regina Elena National Cancer Institute, Rome 00128, Italy.

Rosanna Sestito (R)

Unit of Preclinical Models and New Therapeutic Agents, IRCCS - Regina Elena National Cancer Institute, Rome 00128, Italy.

Andrea Zancla (A)

Department of Engineering, Università Campus Bio-Medico di Roma, via Álvaro del Portillo 21, Rome 00128, Italy; Department of Engineering, Università degli Studi Roma Tre, via Vito Volterra 62, Rome 00146, Italy.

Alberto Rainer (A)

Department of Engineering, Università Campus Bio-Medico di Roma, via Álvaro del Portillo 21, Rome 00128, Italy; Institute of Nanotechnology (NANOTEC), National Research Council (CNR), c/o Campus Ecotekne, via Monteroni, Lecce 73100, Italy.

Anna Bagnato (A)

Unit of Preclinical Models and New Therapeutic Agents, IRCCS - Regina Elena National Cancer Institute, Rome 00128, Italy.

Laura Rosanò (L)

Unit of Preclinical Models and New Therapeutic Agents, IRCCS - Regina Elena National Cancer Institute, Rome 00128, Italy; Institute of Molecular Biology and Pathology, National Research Council (CNR), Rome 00185, Italy. Electronic address: laura.rosano@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH